15 years’ survey of safety and efficacy of <i>Serenoa repens</i> extract in benign prostatic hyperplasia patients with risk of progression

Vinarov, A Z; Spivak, Leonid; Platonova, D V; Rapoport, L.; Korolev, Dmitry

doi:10.1177/0391560318772466

Cited by 16 publications

(20 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This previous study also showed that Permixon treatment led to an improvement in LUTS symptoms, and an inhibition in the progression of BPH, that was equivalent to that achieved with a 6-month treatment with 5-ARIs (Vela-Navarrete et al, 2018). A 15-year open observation study investigated the changes in PV, Q-max, QOL, and IPSS, in BPH patients treated with a daily dose of S. palmetto extract (320 mg), and found that this extract was able to prevent the progression of BPH (Vinarov et al, 2019).…”

Section: Plant Extractsmentioning

confidence: 99%

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Yan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common benign disease of the prostate gland and is caused by benign hyperplasia of the smooth muscle cells and stromal cells in this important gland. BPH is also the most common disease underlying lower urinary tract symptoms (LUTS). The incidence of BPH increases with age and affects more than half of all men 50 years or older. BPH mainly exerts effects on urinary function and can seriously reduce a patient's quality of life. At present, treatment for BPH aims primarily to improve the quality of life and reduce the risk of BPH-related complications. Pharmacological therapy is recommended for moderate-to-severe cases of LUTS that are suggestive of BPH. A range of drugs is currently available to treat this condition, including a1adrenoceptor antagonists, 5a-reductase inhibitors (5-ARIs), phosphodiesterase type 5 inhibitors (PDE5Is), muscarinic receptor antagonists (MRAs), b3-adrenoceptor agonists, and plant extracts. Of these, the most commonly used drugs in the clinic are a1adrenoceptor antagonists, 5-ARIs, and combination therapy. However, these drugs exert their effects via various mechanisms and are associated with adverse reactions. The purpose of this review is to provide current comprehensive perspectives on the mechanisms of action, efficacy, and adverse reactions associated with the drugs most commonly used for the treatment of BPH.

show abstract

Section: Plant Extractsmentioning

confidence: 99%

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Yan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In the extensive review of peer-reviewed literature on LSESr, a safety profile of high tolerability and low side effects has been a consistent finding. A collection of 50 articles focused on the safety and tolerability of LSESr, with eight having study durations ranging from two to fifteen years [23,27,29,[31][32][33][34][35]. Safety and tolerability of LSESr were never issues of concern as per the Cochrane reviews, multiple meta-analyses, and the EMA monograph.…”

Section: Lsesr Has a High Safety Profile In Contrast To Counterpart Prescription Drugsmentioning

confidence: 99%

“…The total number of patients involved in all 17 studies was 1,976. Two studies used a hypercritical CO2 extract of Serenoa repens (hCESr) [111,112], 5 studies employed a hexanic extract of Serenoa repens (HESr) [23,32,33,113], and 10 studies evaluated an ethanolic extract of Serenoa repens (EESr) [24,[27][28][29]31,34,35,107,114,115]. The average change in IPSS, QoL, and Qmax across all studies was -4.8, -1.6, and +3.0 ml/s, respectively.…”

Section: The Response To Lsesr Vs Luts Is Durablementioning

confidence: 99%

<i>Serenoa repens</i> (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Strum¹

2021

Preprint

View full text Add to dashboard Cite

Part I of this 3-part series provided the groundwork for understanding the role of a standardized lipidosterolic extract of Serenoa repens (LSESr) in the treatment of LUTS. It documented that a treatment having a high therapeutic index (i.e., a ratio of benefit to adverse reactions) is a critical need in the demographic context of a rapidly growing elder population. Part I described the clinical symptomatology of LUTS and how it is quantified. A critique of the reports from four authoritative bodies: the European Scientific Cooperative on Phytotherapy (ESCOP), Cochrane 2012, the European Medicines Agency (EMA), and the AUA (American Urological Association) was presented. The foundation above then fine-tuned our search to require (a) consistent evaluability criteria, (b) the quantification of clinical findings, (c) the need to focus on studies employing a standardized LSESr product meeting the fatty acid profile set forth by the European Medicines Agency (EMA) and the US Pharmacopeia and (d) a global assessment of scientific investigations published in all languages and not limited to only English. Part II details the following “new” findings when LSESr vs. LUTS is examined with the above constraints.

show abstract

“…Цим аспектом виступає рівень небажаних побічних явищ (НЯ). Згідно даних 15-річного дослідження російських вчених, використання екстракту Serenoa repens є перспективним напрямком консервативного лікування ДГПЗ, із розвитком довгострокового ефекту покращення сечовипускання та відтермінування виникнення ускладнень у формі гострої затримки сечі [8].…”

Section: а к т у а л ь н ы е т е м ыunclassified

Research PROSPECT IV (PROStamol: PErspectives of Combination Therapy) in Patients with Benign Prostatic Hyperplasia

Гурженко¹,

Спиридоненко²

2020

View full text Add to dashboard Cite

The objective: was to determine the efficacy and safety of nine-year therapy in patients with benign prostatic hyperplasia (ВРН) using the combination «Flosin – Prostamol Uno» by the method of assessing the quality of life and the possibility of improving objective data of urological status. The ultimate goal of nine-year follow-up of patients was to reduce the risk of developing acute urinary retention as a complication of this disease.Materials and methods. A study of patients with BPH who were included in PROSPECT IV found that 37 people from the entire cohort at the age of 59–78 years (68.2±4.7) remained under observation for 2020 (of n=94 in PROSPECT III – 39.3 % of patients were followed up for 9 years). In a similar way, the subjects were randomized according to the conditions of previous therapy into two groups: the І group (clinical) included 33 patients who received the combination «Flosin – Prostamol Uno» for 9 years; ІІ group (control) consisted of 4 subjects who received a combination «doxazosin – finasteride» also for 9 years.Results. The obtained results testify to the high therapeutic efficacy of the combination «Flosin – Prostamol Uno», comparable to the combination of drugs «doxazosin and finasteride». Combination therapy with Flosin and Prostamol Uno was well tolerated in patients with a low incidence of adverse events (5.75 %; p <0.05) compared with patients receiving the combination of doxazosin and finasteride (27 %, p <0, 05). 7 (18.9 %) patients were operated on during the last 5 years (TUR – 6; laser vaporization – 1); the level of acute urinary retention – in 7 people in the form of 1–2 episodes, which required operative assistance.Conclusion. The above facts made it possible to assert that: the adherence of patients to the combined conservative therapy of BPH according to the «Flosin – Prostamol Uno» scheme was high (43.2 %); adherence of patients operated on for acute urinary retention to this type of combination therapy was evident (all patients received Extr. Serenoa repens and tamsulosin in the postoperative period); the level of acute urinary retention in persons of group I with BPH who received treatment for 9 years was 19 % (p> 0.05).

show abstract

15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression

Abstract: The 15 years' study results suggest that taking S. repens plant extract continuously at a daily dose of 320 mg is an effective and safe way to prevent the progression of benign prostatic hyperplasia.

Cited by 16 publications

References 7 publications

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

<i>Serenoa repens</i> (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Research PROSPECT IV (PROStamol: PErspectives of Combination Therapy) in Patients with Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About